21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Period: 27.03.2026 Expectation: 1050 pips
AUDCAD thrives on monetary divergence
Today at 10:06 AM 4
Period: 31.03.2026 Expectation: 800 pips
Buying Brent crude with $115 in view
Today at 09:35 AM 7
Gold sell
Period: 31.03.2026 Expectation: 600 pips
Selling gold upon breaking $4,560
Today at 08:46 AM 7
Period: 30.04.2026 Expectation: 2000 pips
SPX selloff to follow once it consolidates below $6,600
Today at 08:46 AM 6
Period: 30.06.2026 Expectation: 3000 pips
Selling GBPUSD down to 1.3500
Today at 04:19 AM 16
Period: 26.03.2026 Expectation: 1100 pips
Selling SPX with $6,510 in sight is key strategy
Yesterday at 11:55 AM 27
Go to forecasts